11:24 AM
 | 
Jan 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amgen to start its first CAR T trial in 1H18

Amgen Inc. (NASDAQ:AMGN) said it plans to start clinical testing of its first chimeric antigen receptor (CAR) T cell therapy this half. The trial will evaluate a single...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >